SPA17
Sperm surface protein Sp17
Also known as: CT22, SP17, SP17_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q15506
- Gene
- SPA17
- Ensembl
- ENSG00000064199
- Chromosome
- 11
- Canonical length
- 151 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Golgi apparatus,Vesicles,Principal piece
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a protein present at the cell surface. The N-terminus has sequence similarity to human cAMP-dependent protein kinase A (PKA) type II alpha regulatory subunit (RIIa) while the C-terminus has an IQ calmodulin-binding motif. The central portion of the protein has carbohydrate binding motifs and likely functions in cell-cell adhesion. The protein was initially characterized by its involvement in the binding of sperm to the zona pellucida of the oocyte. Recent studies indicate that it is also involved in additional cell-cell adhesion functions such as immune cell migration and metastasis. A retrotransposed pseudogene is present on chromosome 10q22.[provided by RefSeq, Jan 2009]
Canonical amino-acid sequenceUniProt
151 residues, UniProt reviewed canonical sequence.
>Q15506|SPA17
1 MSIPFSNTHY RIPQGFGNLL EGLTREILRE QPDNIPAFAA AYFESLLEKR EKTNFDPAEW
61 GSKVEDRFYN NHAFEEQEPP EKSDPKQEES QISGKEEETS VTILDSSEED KEKEEVAAVK
121 IQAAFRGHIA REEAKKMKTN SLQNEEKEEN KLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SPA17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.51
- Highest tissue expression
- 37 nTPM
Expression across tissuesHPA
Tissue
- testis: 37 nTPM
- fallopian tube: 23 nTPM
- choroid plexus: 15 nTPM
- epididymis: 10 nTPM
- thyroid gland: 6.3 nTPM
- parathyroid gland: 4.4 nTPM
Single-cell type
- late spermatids: 3,590 nCPM
- late primary spermatocytes: 1,869 nCPM
- early spermatids: 1,487 nCPM
- fallopian tube ciliated cells: 537 nCPM
- respiratory ciliated cells: 477 nCPM
- endometrial ciliated cells: 397 nCPM
Immune cell
- non-classical monocyte: 0.6 nTPM
- basophil: 0.5 nTPM
- myeloid DC: 0.4 nTPM
- classical monocyte: 0.3 nTPM
- intermediate monocyte: 0.2 nTPM
- memory B-cell: 0.1 nTPM
Brain region
- choroid plexus: 17 nTPM
- midbrain: 8.6 nTPM
- medulla oblongata: 8.4 nTPM
- spinal cord: 6.4 nTPM
- thalamus: 5.2 nTPM
- white matter: 5.1 nTPM
ReferencesPubMed · IEDB
Publications for SPA17 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
6 publications
- Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome reaction.
1994 · Dev Biol · RCR 3.1 · 101 citations - Autoimmunogenicity of the human sperm protein Sp17 in vasectomized men and identification of linear B cell epitopes.
1997 · Fertil Steril · RCR 0.9 · 35 citations - Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer.
2007 · Int J Cancer · RCR 0.6 · 27 citations - The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.
2017 · Oncotarget · RCR 0.4 · 11 citations - [Detection of anti-Sp17 antibodies in infertile patients' serum and its clinical significance].
2007 · Zhonghua Nan Ke Xue · RCR 0.1 · 4 citations
Show 1 more
- Serum Sp17 Autoantibody Serves as a Potential Specific Biomarker in Patients with SAPHO Syndrome.
2021 · J Clin Immunol · RCR 0.1 · 1 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.4
- gnomAD pLI
- 0.01
- gnomAD missense Z
- -0.16
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- binding of sperm to zona pellucida
- epithelial cilium movement involved in extracellular fluid movement
- single fertilization
- spermatogenesis
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SPA17 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SPA17 as an antibody target. Whether an autoantibody or antibody against SPA17 could matter depends on whether native SPA17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SPA17 is annotated at the cell surface, where native SPA17 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SPA17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...